{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:52:24Z","timestamp":1792119144654,"version":"4.4.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001797","name":"Pharmaceutical Research and Manufacturers of America Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001797","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ajog.2022.02.012","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T20:48:53Z","timestamp":1645217333000},"page":"722.e1-722.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3705-6943","authenticated-orcid":false,"given":"Rupsa C.","family":"Boelig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina N.","family":"Schoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9244-0745","authenticated-orcid":false,"given":"Heather","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-8995","authenticated-orcid":false,"given":"Alexis C.","family":"Gimovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Springel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Backley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Berghella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2022.02.012_bib1","first-page":"1","article-title":"Describing the increase in preterm births in the United States, 2014-2016","author":"Martin","year":"2018","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.ajog.2022.02.012_bib2","first-page":"1","article-title":"Births: final data for 2019","volume":"70","author":"Martin","year":"2021","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.ajog.2022.02.012_bib3","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1073\/pnas.54.4.1069","article-title":"The effect of progesterone on the human uterus","volume":"54","author":"Csapo","year":"1965","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajog.2022.02.012_bib4","doi-asserted-by":"crossref","first-page":"353297","DOI":"10.1155\/2011\/353297","article-title":"Progesterone interactions with the cervix: translational implications for term and preterm birth","volume":"2011","author":"Larsen","year":"2011","journal-title":"Infect Dis Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.02.012_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081340","article-title":"Loss of progesterone receptor-mediated actions induce preterm cellular and structural remodeling of the cervix and premature birth","volume":"8","author":"Yellon","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ajog.2022.02.012_bib6","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/1933719116650756","article-title":"Progesterone receptor-mediated actions regulate remodeling of the cervix in preparation for preterm parturition","volume":"23","author":"Kirby","year":"2016","journal-title":"Reprod Sci"},{"key":"10.1016\/j.ajog.2022.02.012_bib7","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41598-017-04759-6","article-title":"Evolution of gene expression in the uterine cervix related to steroid signaling: conserved features in the regulation of cervical ripening","volume":"7","author":"Wagner","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajog.2022.02.012_bib8","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.ajpath.2012.08.036","article-title":"Abruption-induced preterm delivery is associated with thrombin-mediated functional progesterone withdrawal in decidual cells","volume":"181","author":"Lockwood","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajog.2022.02.012_bib9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/path.4589","article-title":"Mechanisms of chorioamnionitis-associated preterm birth: interleukin-1\u03b2 inhibits progesterone receptor expression in decidual cells","volume":"237","author":"Guzeloglu-Kayisli","year":"2015","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.ajog.2022.02.012_bib10","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2010282118","article-title":"Decidual cell FKBP51-progesterone receptor binding mediates maternal stress-induced preterm birth","volume":"118","author":"Guzeloglu-Kayisli","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajog.2022.02.012_bib11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/j.semperi.2016.03.002","article-title":"What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth","volume":"40","author":"Caritis","year":"2016","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.ajog.2022.02.012_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ajog.2015.10.934","article-title":"Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety","volume":"214","author":"O\u2019Brien","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.02.012_bib13","doi-asserted-by":"crossref","first-page":"520.e1","DOI":"10.1016\/j.ajog.2015.06.014","article-title":"Progesterone inhibits in\u00a0vitro fetal membrane weakening","volume":"213","author":"Kumar","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.02.012_bib14","doi-asserted-by":"crossref","first-page":"695.e1","DOI":"10.1016\/j.ajog.2017.10.004","article-title":"In an in-vitro model using human fetal membranes, 17-\u03b1 hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening","volume":"217","author":"Kumar","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.02.012_bib15","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa035140","article-title":"Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate","volume":"348","author":"Meis","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2022.02.012_bib16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-0039-3400227","article-title":"17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): a multicenter, international, randomized double-blind trial","volume":"37","author":"Blackwell","year":"2020","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajog.2022.02.012_bib17","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(21)00217-8","article-title":"Evaluating Progestogens for Preventing preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2022.02.012_bib18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1067\/mob.2003.41","article-title":"Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study","volume":"188","author":"da Fonseca","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.02.012_bib19","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/uog.5158","article-title":"Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial","volume":"30","author":"O\u2019Brien","year":"2007","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.02.012_bib20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/uog.17245","article-title":"Vaginal progesterone vs intramuscular 17\u03b1-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: systematic review and meta-analysis of randomized controlled trials","volume":"49","author":"Saccone","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.02.012_bib21","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/1471-0528.15566","article-title":"Vaginal progesterone, oral progesterone, 17-OHPC, cerclage, and pessary for preventing preterm birth in at-risk singleton pregnancies: an updated systematic review and network meta-analysis","volume":"126","author":"Jarde","year":"2019","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2022.02.012_bib22","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1097\/AOG.0000000000004479","article-title":"Prediction and prevention of spontaneous preterm birth: ACOG Practice Bulletin, Number 234","volume":"138","year":"2021","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.02.012_bib23","doi-asserted-by":"crossref","first-page":"B11","DOI":"10.1016\/j.ajog.2017.01.022","article-title":"The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth","volume":"216","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.02.012_bib25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J\u00a0Biomed Inform"},{"key":"10.1016\/j.ajog.2022.02.012_bib26","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software partners","volume":"95","author":"Harris","year":"2019","journal-title":"J\u00a0Biomed Inform"},{"key":"10.1016\/j.ajog.2022.02.012_bib27","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"152","author":"Schulz","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajog.2022.02.012_bib28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12874-021-01362-2","article-title":"Use of research electronic data capture (REDCap) in a COVID-19 randomized controlled trial: a practical example","volume":"21","author":"Kianersi","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ajog.2022.02.012_bib29","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1053\/j.semperi.2017.08.003","article-title":"Current options for mechanical prevention of preterm birth","volume":"41","author":"Boelig","year":"2017","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.ajog.2022.02.012_bib30","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/01.AOG.0000443276.68274.cc","article-title":"ACOG Practice Bulletin No.142: cerclage for the management of cervical insufficiency","volume":"123","year":"2014","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.02.012_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ajog.2017.11.576","article-title":"Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data","volume":"218","author":"Romero","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.02.012_bib32","article-title":"\u201dQuestion and Questionnaire Design.\u201d Chapter 9 in Handbook of Survey Research. 2nd Edition","author":"Krosnick","year":"2010","journal-title":"Emerald Group Publishing"},{"key":"10.1016\/j.ajog.2022.02.012_bib33","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1001\/jama.294.17.2228","article-title":"When (not) to stop a clinical trial for benefit","volume":"294","author":"Pocock","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2022.02.012_bib34","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(05)66516-6","article-title":"Multiplicity in randomised trials II: subgroup and interim analyses","volume":"365","author":"Schulz","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2022.02.012_bib35","doi-asserted-by":"crossref","first-page":"371.e1","DOI":"10.1016\/j.ajog.2017.05.022","article-title":"Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth","volume":"217","author":"Ning","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.02.012_bib36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijgo.2016.01.010","article-title":"A\u00a0randomized controlled trial of intramuscular versus vaginal progesterone for the prevention of recurrent preterm birth","volume":"134","author":"Elimian","year":"2016","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ajog.2022.02.012_bib37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/AOG.0000000000001841","article-title":"A\u00a0statewide progestogen promotion program in Ohio","volume":"129","author":"Iams","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.02.012_bib38","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.clinthera.2015.01.007","article-title":"17\u03b1-Hydroxyprogesterone caproate access in the Louisiana Medicaid population","volume":"37","author":"Orsulak","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.ajog.2022.02.012_bib39","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1080\/14767058.2018.1481035","article-title":"Utilization of progesterone and cervical length screening for prevention of recurrent preterm birth","volume":"32","author":"Boelig","year":"2019","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2022.02.012_bib40","first-page":"295","article-title":"Patient and provider perspectives on acceptability, access, and adherence to 17-alpha-hydroxyprogesterone caproate for preterm birth prevention","volume":"2","author":"Garcia","year":"2021","journal-title":"Womens Health Rep (New Rochelle)"},{"key":"10.1016\/j.ajog.2022.02.012_bib41","doi-asserted-by":"crossref","first-page":"263.e1","DOI":"10.1016\/j.ajog.2019.06.019","article-title":"Pharmacokinetics of vaginal progesterone in pregnancy","volume":"221","author":"Boelig","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.02.012_bib42","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/bcp.12990","article-title":"Population pharmacokinetics of 17\u03b1-hydroxyprogesterone caproate in singleton gestation","volume":"82","author":"Sharma","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ajog.2022.02.012_bib43","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/1471-0528.13744","article-title":"Pharmacogenomics of preterm birth prevention and treatment","volume":"123","author":"Manuck","year":"2016","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2022.02.012_bib44","doi-asserted-by":"crossref","first-page":"321.e1","DOI":"10.1016\/j.ajog.2014.01.013","article-title":"Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention","volume":"210","author":"Manuck","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.02.012_bib45","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/1471-0528.14485","article-title":"Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth: a case-control study","volume":"125","author":"Manuck","year":"2018","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2022.02.012_bib46","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1055\/s-0040-1710008","article-title":"Predictors of early preterm birth despite vaginal progesterone therapy in singletons with short cervix","volume":"37","author":"Boelig","year":"2020","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajog.2022.02.012_bib47","doi-asserted-by":"crossref","first-page":"B16","DOI":"10.1016\/j.ajog.2020.04.001","article-title":"SMFM statement: use of 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth","volume":"223","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.02.012_bib48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/biores.2019.0010","article-title":"Improving uptake and adherence to 17-hydroxyprogesterone caproate in non-Hispanic Black women: a mixed methods study of potential interventions from the patient perspective","volume":"8","author":"Wheeler","year":"2019","journal-title":"Biores Open Access"},{"key":"10.1016\/j.ajog.2022.02.012_bib49","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/1471-0528.16365","article-title":"Vaginal compared with intramuscular progestogen for preventing preterm birth in high-risk pregnant women (VICTORIA study): a multicentre, open-label randomised trial and meta-analysis","volume":"127","author":"Choi","year":"2020","journal-title":"BJOG"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937822001156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937822001156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:37:09Z","timestamp":1762079829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937822001156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0002937822001156"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2022.02.012","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2022.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}